Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Year range
1.
J. bras. med ; 101(02): 13-18, mar.-abr. 2013. tab
Article in Portuguese | LILACS | ID: lil-686288

ABSTRACT

As fraturas atípicas do fêmur são raras, mas sua crescente descrição na literatura e sua provável associação com os bifosfonatos trouxeram à tona uma série de aspectos ainda nebulosos no tocante ao uso contínuo dessas drogas. O protocolo mais sugerido atualmente, embora ainda não totalmente estabelecido, orienta a retirada da medicação após três a cinco anos de uso contínuo dos bifosfonatos, retornando cerca de três anos depois, quando houver necessidade


Atypical femur fractures are rare but a growing concern, as they are more common in patients who use long-term bisphosphonates. This brought to light a number of issues still unknown regarding the continued use of these drugs. Nowadays the most suggested protocol, although not yet fully esbablished, considers not more than three to five years of bisphosphonate treatment for osteoporotic patients, returning about three years later, when the need arises


Subject(s)
Humans , Male , Female , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Femoral Fractures/etiology , Diaphyses , Diphosphonates/adverse effects , Diphosphonates/pharmacology , Fracture Fixation, Intramedullary , Hip Fractures , Osteoporosis/physiopathology , Osteoporosis/drug therapy , Teriparatide/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL